Early Development Still Driving CRO Performance

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-09-02-2004
Volume 28
Issue 9

Early development services continue to be a sweet spot for contract R&D services. The big question is how soon the impact of early-development candidates will be felt in late development and commercialization.

External Link - article-122722.pdf

Articles in this issue
Excel file and formula for Determining Probability of Passing the USP Content Uniformity Test
In the Spotlight-September 2004
Promoting Quality in Drug Manufacturing
Automation in a Digital, Webbed, and Wireless Age
September 2004
Design of an Aseptic Process Simulation
Use of the Bergum Method and MS Excel to Determine the Probability of Passing the USP Content Uniformity Test
Characterization of the Performance of Bin Blenders-Part 3 of 3: Cohesive Powders
Early Development Still Driving CRO Performance
Particulate-Free Pallets
Recent Videos
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Circio and Certest to Collaborate on LNP Formulations

Feliza Mirasol
November 21st 2024
Article

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Felicity Thomas
July 11th 2023
Podcast

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

Feliza Mirasol
November 20th 2024
Article

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Drug Solutions Podcast: Examining the State of Biopharma Investment

Drug Solutions Podcast: Examining the State of Biopharma Investment

Grant Playter
June 6th 2023
Podcast

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Avantor Sees Future of Opportunities with Growing Development of Next-Gen Biotherapeutics

Feliza Mirasol
November 15th 2024
Article

Executives at Avantor talk about the future of the biopharmaceutical industry and the anticipated impact that a wave of next-generation biotherapeutics will bring.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Merck and Ginkgo Bioworks’ Collaboration to Improve Biologics Manufacturing Has Reached Its First Milestone

Feliza Mirasol
November 13th 2024
Article

Under an ongoing partnership with Merck, known as MSD outside of the United States and Canada, Ginkgo Bioworks has achieved the first milestone in a project aimed at improving biologics production.